← Back to Search

Dietary Supplement

Natural Anti-Inflammatory Supplements for Osteoarthritis

Phase 2 & 3
Waitlist Available
Led By Javad Parvizi, MD
Research Sponsored by Physician Recommended Nutriceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Lequesne's Functional Index score greater than 7 points
Subjects with symptomatic moderate arthritis of the knee defined as per Kellgren-Lawrence grade II or III
Must not have
Subjects with systemic inflammatory conditions such as inflammatory bowel disease, psoriasis, eczema, and others
Subjects taking hormone replacement therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks

Summary

This trial will test a new joint supplement against a placebo and another supplement. It will start in July 2014 and finish in July 2015, enrolling subjects at random.

Who is the study for?
Adults aged 18-90 with moderate knee osteoarthritis, able to walk unassisted and have a specific score on the Lequesne's Functional Index can join. Excluded are those with systemic inflammatory conditions, hormone therapy users, recent recipients of corticosteroid injections in the knee, fish oil allergies, heavy drinkers, pregnant or breastfeeding women, and those taking certain supplements.
What is being tested?
The study is testing an anti-inflammatory product called PRN Joint Health Formula against a placebo and another combination product (PRN Flex Omega Benefits®). Participants will be randomly assigned to one of these treatments in equal numbers at each site.
What are the potential side effects?
Potential side effects may include allergic reactions for those sensitive to fish oil (in the active treatment groups), digestive issues due to supplement intake, and possible interactions with other medications or supplements not disclosed.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My knee pain affects my daily activities significantly.
Select...
I have moderate knee arthritis.
Select...
I can walk 50 feet by myself.
Select...
I am between 18 and 90 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a condition like inflammatory bowel disease, psoriasis, or eczema.
Select...
I am currently on hormone replacement therapy.
Select...
I do not have allergies to NSAIDs, liver or kidney issues, history of stomach ulcers or bleeding, heart failure, high blood pressure, cancer, or high potassium levels.
Select...
I do not have significant blood, clotting, or nerve disorders.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Human Inflammation Multi analyte profile (MAP) v1.0 in Synovial fluid and blood

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Joint Health ProductExperimental Treatment1 Intervention
natural dietary supplement
Group II: Combination with Omega-3Active Control1 Intervention
combination with omega-3 fish oil
Group III: PlaceboPlacebo Group1 Intervention
vegetable oil placebo

Find a Location

Who is running the clinical trial?

Physician Recommended NutriceuticalsLead Sponsor
4 Previous Clinical Trials
322 Total Patients Enrolled
Rothman Institute OrthopedicsUNKNOWN
Javad Parvizi, MDPrincipal InvestigatorRothman Institute
2 Previous Clinical Trials
130 Total Patients Enrolled
1 Trials studying Osteoarthritis
80 Patients Enrolled for Osteoarthritis

Media Library

placebo (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT02333084 — Phase 2 & 3
Osteoarthritis Research Study Groups: Joint Health Product, Placebo, Combination with Omega-3
Osteoarthritis Clinical Trial 2023: placebo Highlights & Side Effects. Trial Name: NCT02333084 — Phase 2 & 3
placebo (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02333084 — Phase 2 & 3
Osteoarthritis Patient Testimony for trial: Trial Name: NCT02333084 — Phase 2 & 3
~10 spots leftby Jan 2026